Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Satoshi, Morishige"'
Autor:
Koichi, Osaki, Yoko, Sogabe, Ritsuko, Seki, Takayuki, Nakamura, Satoshi, Morishige, Eijiro, Oku, Yuka, Takata, Fumihiko, Mouri, Koji, Yoshimoto, Koji, Nagafuji, Takashi, Okamura
Publikováno v:
The Kurume medical journal. 67(2.3)
We investigated the molecular basis of factor VII (FVII) deficiency in a Japanese patient and identified compound heterozygous mutations. Factor VII activity and antigen levels in the patient were less than 5.0% and 6.5% of controls, respectively. Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::39f0173a513a276b26aae64b047d75e6
https://pubmed.ncbi.nlm.nih.gov/36123027
https://pubmed.ncbi.nlm.nih.gov/36123027
Autor:
Kazutoshi, Aoyama, Yoshitaka, Yamasaki, Fumihiko, Mouri, Yoshimi, Maehiro, Yusuke, Takaki, Shuki, Oya, Takayuki, Nakamura, Satoshi, Morishige, Maki, Yamaguchi, Koji, Nagafuji
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(7)
FMS-like tyrosine kinase 3 (FLT3) inhibitors improve the prognosis of FLT3-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML). Case 1 is a 47-year-old male patient who presented with a white blood cell count (WBC) of 95,700/ml wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::79199bdc5c3973c30e7cc4c7d2432555
https://pubmed.ncbi.nlm.nih.gov/35922945
https://pubmed.ncbi.nlm.nih.gov/35922945
Autor:
Naoyuki Uchida, Masahiko Hara, Hisashi Yamamoto, Toshiro Kawakita, Yumiko Maruyama, Takahiro Fukuda, Takashi Ashida, Yoshiko Atsuta, Atsushi Wake, Takashi Ikeda, Tatsuo Ichinohe, Takayuki Ishikawa, Satoshi Morishige, Yoshimitsu Shimomura, Satoru Takada, Minoko Takanashi
Publikováno v:
Bone Marrow Transplantation. 56:1691-1699
Fludarabine and a myeloablative dose of busulfan (Flu/Bu4) can improve prognosis after allogeneic hematopoietic stem cell transplantation (HSCT) with melphalan (Mel). We investigated the prognostic impact of adding Mel to Flu/Bu4 by comparing between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40964815da380988554f22a638158447
https://doi.org/10.1038/s41409-021-01217-w
https://doi.org/10.1038/s41409-021-01217-w
Autor:
Kazutoshi Aoyama, Koichi Osaki, Kenta Murotani, Yoshitaka Yamasaki, Takuro Imai, Takayuki Nakamura, Maki Yamaguchi, Yusuke Takagi, Takuma Hazama, Shuki Oya, Fumihiko Mouri, Koji Nagafuji, Koichi Egashira, Satoshi Morishige
Publikováno v:
Journal of Hematopoietic Cell Transplantation. 10:129-135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28304c4b6e11ed40d0447a2cb798ec75
https://doi.org/10.7889/hct-20-022
https://doi.org/10.7889/hct-20-022
Autor:
Satoshi, Morishige, Yoshitaka, Yamasaki, Shuki, Oya, Takayuki, Nakamura, Maki, Yamaguchi, Kazutoshi, Aoyama, Fumihiko, Mouri, Yasuko, Mizushima, Osamu, Nakashima, Koji, Nagafuji
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(4)
Inotuzumab ozogamicin (InO) was administered in three cases of relapsed/refractory adult acute lymphoblastic leukemia (ALL) before allogeneic hematopoietic stem cell transplantation (allo-SCT). One case developed extremely severe sinusoidal obstructi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4da99a7d5862ebcf36b61e56a7726868
https://pubmed.ncbi.nlm.nih.gov/35491216
https://pubmed.ncbi.nlm.nih.gov/35491216
Autor:
KOICHI OSAKI, YOKO SOGABE, RITSUKO SEKI, TAKAYUKI NAKAMURA, SATOSHI MORISHIGE, EIJIRO OKU, YUKA TAKATA, FUMIHIKO MOURI, KOJI YOSHIMOTO, KOJI NAGAFUJI, TAKASHI OKAMURA
Publikováno v:
The Kurume Medical Journal. 67:83-89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b46c69b569f4e626e06ba173d36f531
https://doi.org/10.2739/kurumemedj.ms6723006
https://doi.org/10.2739/kurumemedj.ms6723006
Autor:
Kazutoshi Aoyama, Ritsuko Seki, Kensuke Sasaki, Yoshitaka Yamasaki, Takahiro Maeda, Takayuki Nakamura, Shuki Oya, Hidetoshi Ozawa, Yuichiro Semba, Koji Nagafuji, Fumihiko Mouri, Koichi Osaki, Toshihiro Miyamoto, Satoshi Morishige
Publikováno v:
International Journal of Hematology. 113:285-289
BCR-ABL1-like acute lymphoblastic leukemia (ALL) is a neoplasm of lymphoblasts committed to the B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of gene expression very similar to that seen in ALL with BCR-ABL1 with poor prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39f5815324cbf616ccdd1a09e1ad211
https://doi.org/10.1007/s12185-020-03006-5
https://doi.org/10.1007/s12185-020-03006-5
Autor:
Fumihiko Mouri, Koichi Osaki, Koji Nagafuji, Ritsuko Seki, Kenji Kuboyama, Takayuki Nakamura, Shuki Oya, Kazutoshi Aoyama, Shinichi Mizuno, Maki Yamaguchi, Takashi Okamura, Hidetoshi Ozawa, Yoshitaka Yamasaki, Satoshi Morishige
Publikováno v:
Haemophilia. 26:826-833
Background Factor V (FV) deficiency is a monogenic inherited coagulation disorder considered to be an ideal indication for gene therapy. To investigate the possibility of therapeutic application of genome editing, we generated induced pluripotent ste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b77f24e0ace7ba34eec32532038fc3f
https://doi.org/10.1111/hae.14104
https://doi.org/10.1111/hae.14104
Autor:
Ahmad Mazahery, Koichi Osaki, Hidetoshi Ozawa, Shinichi Mizuno, Takayuki Nakamura, Fumihiko Mouri, Koji Nagafuji, Satoshi Morishige, Ritsuko Seki, Ken Ichi Yamamura, Takashi Okamura, Kei Nomura
Publikováno v:
International Journal of Hematology. 111:225-233
The clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system is an efficient genome-editing tool that holds potential for gene therapy. Here, we report an application of this system for gene repair in hemophi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8acf8eb66cb48e8aa86aa541b3c67e9
https://doi.org/10.1007/s12185-019-02765-0
https://doi.org/10.1007/s12185-019-02765-0
Autor:
Ritsuko Seki, Koichi Osaki, Shuki Oya, Takayuki Nakamura, Fumiko Arakawa, Hiroshi Saruta, Marina Nishi, Maki Yamaguchi, Satoshi Morishige, Koichi Ohshima, Kazutoshi Aoyama, Yoshitaka Yamasaki, Fumihiko Mouri, Koji Nagafuji
Publikováno v:
International Journal of Hematology. 110:506-511
Allogeneic hematopoietic cell transplantation (allo-HSCT) is considered the curative treatment option in patients with aggressive adult T cell leukemia/lymphoma (ATLL), but the treatment of relapse after allo-HSCT remains a major challenge. We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004b5457a9446d29b9b448242a745524
https://doi.org/10.1007/s12185-019-02675-1
https://doi.org/10.1007/s12185-019-02675-1